...
首页> 外文期刊>Facial plastic surgery & aesthetic medicine. >The Effects of Lateral Crural Tensioning with an Articulated Alar Rim Graft Versus Lateral Crural Strut Graft on Nasal Function
【24h】

The Effects of Lateral Crural Tensioning with an Articulated Alar Rim Graft Versus Lateral Crural Strut Graft on Nasal Function

机译:用铰接的Alar轮辋移植与外侧弯曲撑杆移植物与鼻弯曲的侧向侧重张力对鼻功能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

abstract_textpImportance: Nasal valve dysfunction can be addressed by various valve reinforcement techniques. There is no consensus on which technique is most efficacious./ppObjective: To evaluate lateral crural tensioning with articulated alar rim grafting (LCT/AARG) versus the lateral crural strut graft (LCSG) for their efficacy as nasal valve reinforcement techniques in rhinoplasty./ppDesign, Setting, and Participants: A cohort study was undertaken on patients who underwent either the LCT/AARG or LCSG as part of their rhinoplasty procedure. Airway testing was performed preoperatively and 6 months after the procedure, with data collected from February 2015 to July 2018 at a single tertiary rhinologic practice. Consecutive adults underwent open structure septorhinoplasty by one surgeon for both cosmetic and functional indications, as both primary and revision cases./ppMain Outcomes and Measures: The primary functional outcomes analyzed were the nasal peak inspiratory flow (NPIF) and total nasal airway resistance (NAR). The primary patient-reported outcome measures analyzed were the visual analogue scale (VAS) for nasal obstruction, the Nasal Obstruction Symptom Evaluation (NOSE), and nasal obstruction score. Data were also normalized as a percentage improvement over preoperative baseline, to account for individual variability./ppResults: In total 94 participants were recruited (33.7 +/- 11.7 years, 85.3% female) with 26.6% in the LCT/AARG group and 73.4% in the LCSG group. Change in NAR (Delta NAR) was significantly better in the AARG group (-18.73 +/- 26.84 Pa/cc(3) vs. 15.07 +/- 55.57 Pa/cc(3), p 0.001). In addition, NAR improved significantly when analysis was isolated to the LCT/AARG group (0.414 +/- 0.255 Pa/(cc(3)center dot s) vs. 0.291 +/- 0.116 Pa/(cc(3)center dot s), Delta = -0.122 Pa/(cc(3)center dot s), p = 0.004) despite change in NAR being insignificant for the entire study population after surgery (0.370 +/- 0.177 Pa/(cc(3)center dot s) vs. 0.349 +/- 0.152 Pa/(cc(3)center dot s), Delta = 0.021, p = 0.320). There were no significant differences between the study groups in Delta NPIF (15.85 +/- 31.48 L/min vs. 8.20 +/- 30.12 L/min, p = 0.285), Delta VAS (35.77 +/- 130.52 vs. 31.38 +/- 73.19, p = 0.838), Delta NOSE (-73.60 +/- 25.43 vs. -27.31 +/- 123.44, p = 0.085), and Delta nasal obstruction (64% experiencing improvement vs. 63.2% experiencing improvement, p = 0.097)./ppConclusions and Relevance: LCT/AARG demonstrated benefit in total NAR over the LCSG. There were no other significant functional differences between the two techniques./p/abstract_text
机译:& atravent_text&& p&重要性:可以通过各种阀加固技术来解决鼻瓣功能障碍。尚无共识,目的是最有效的。鼻腔成形术中的鼻瓣增强技术。/p&&& p& p&设计,设置和参与者:对接受LCT/AARG或LCSG作为其隆鼻手术的一部分的患者进行了一项队列研究。该手术后的术前和6个月进行了气道测试,从2015年2月至2018年7月收集了单个第三级隆静实践的数据。一名外科医生的连续成年人对化妆品和功能指示进行了开放结构,作为原发性和修订案例。 )和总鼻气道阻力(NAR)。分析的主要患者报告的结果指标是鼻阻塞,鼻阻塞症状评估(鼻子)和鼻阻塞评分的视觉模拟量表(VAS)。数据还标准化为术前基线的百分比,以说明个体可变性。在LCT/AARG组中,LCSG组为73.4%。在AARG组(-18.73 +/- 26.84 PA/CC(3)vs. 15.07 +/- 55.57 +/- 55.57 PA/CC(3),P< 0.001)中,NAR(Delta NAR)的变化明显好得多。此外,当分析分析到LCT/AARG组时,NAR显着改善(0.414 +/- 0.255 PA/(CC(3)中心点)与0.291 +/- 0.116 PA/(CC(3)中心点S ),delta = -0.122 pa/(cc(3)中心点),p = 0.004),尽管NAR的变化在手术后的整个研究人群无关紧要(0.370 +/- 0.177 PA/(CC(CC(3)中心点) s)vs. 0.349 +/- 0.152 pa/(cc(3)中心点),delta = 0.021,p = 0.320)。 Delta NPIF中研究组之间没有显着差异(15.85 +/- 31.48 l/min vs. 8.20 +/- 30.12 l/min,p = 0.285),delta vas(35.77 +/- 130.52 vs. 31.38 +/ +/ -73.19,p = 0.838),delta鼻子(-73.60 +/- 25.43 vs. -27.31 +/- 123.44,p = 0.085)和鼻腔阻塞(64%的体验改善,63.2%的经历,p = 0.0977797 )。&/p&& p&结论与相关性:LCT/AARG在NAR中表现出比LCSG的好处。两种技术之间没有其他显着的功能差异。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号